anti-natriuretic responses to stress in spontaneously hypertensive rats Objective-To determine the effect of oxpentifylline on the healing of venous ulcers of the leg.
Design-Double blind, randomised, prospective, placebo controlled, parallel group study.
Setting-Four outpatient clinics treating leg ulcers in England and the Republic of Ireland.
Patients-80 Consecutive patients with clinical evidence of venous ulceration of the leg in whom appreciable arterial disease was excluded by the ratio of ankle to brachial systolic pressure being >0*8.
Interventions-All patients received either oxpentifylline 400 mg three times a day by mouth or a matching placebo for six months (or until their reference ulcer healed if this occurred sooner) in addition to a locally standardised method of compression bandaging.
Main outcome measures-The primary end point was complete healing of the reference ulcer within six months. The secondary end point was the change in the area of the ulcer over the six month observation period.
Results-Complete healing of the reference ulcer occurred in 23 of the 38 patients treated with oxpentifylline and in 12 of the 42 patients treated with a placebo. Life table analysis showed that the proportion of ulcers healed at six months was 64% in the group treated with oxpentifylline compared with 34% in the group treated with a placebo (log rank
Introduction
Venous ulcers of the leg are a common cause of illness in the community. The condition has a prevalence of 1%, which is similar to that of diabetes, and it recurs chronically.' Ulcers of the leg are expensive to treat as they require regular dressing, often by district nurses. The cost to the NHS has been estimated to be £1200 for each unhealed ulcer a year. this drug in patients with venous ulceration of the leg.
Patients and methods
The trial design was a prospective, randomised, double blind, placebo controlled, parallel group study of 80 patients and was conducted in four centres in England and the Republic of Ireland. Consecutive eligible patients attending the leg ulcer clinic at each centre were randomised to receive either oxpentifylline (400 mg three times a day by mouth) or a matching placebo. Randomisation was performed in balanced blocks of eight with a separate list for each centre. Treatment was continued for six months or until the ulcer healed if this occurred sooner.
Patients with ulcers that had shown no signs of healing after at least two months of routine outpatient treatment were considered to be eligible for entry into the study, provided that the ulceration was clinically thought to be of venous origin, that the ratio of ankle to brachial systolic pressure was >0 8, and that there was no contraindication to the prescription of oxpentifylline. " The largest ulcer present was selected to be monitored as the reference ulcer for the duration of the study, provided that its diameter was between 2 cm and 15 cm. At the initial visit the reference ulcer was traced with an indelible pen on to a transparent acetate sheet.' The number of additional leg ulcers was also documented. Patients were seen every two weeks for six months and the reference ulcers were traced at alternate visits. An ulcer was considered to be healed only when complete re-epithelialisation had occurred.
Details of the dressings used in the four centres were recorded. Each centre used a two layer method of bandaging that was capable of producing adequate graduated compression." The bandaging method was standardised at each centre within the limits of clinical practice. All centres liaised closely with the local community or district nursing services to ensure continuity of the patients' dressings at home between study visits.
A computerised system was developed to measure the area of the ulcers from the tracing. (AUTOCAD software adapted by Datech, Orpington, Kent). All measurements were nmade by one trained observer, and the average of two readings was used for analysis.
Descriptive statistics were used to characterise the treatment groups at baseline.'4 The statistical methods included the X) test and the log rank test, which was used to compare the two treatment groups for overall healing of ulcers. The odds ratio was calculated for the rate of ulcer healing.
The trial was conducted in accordance with the Declaration of Helsinki (Venice amendment), and the protocol of the study was approved by the ethics committee at each centre. The informed consent of each patient was obtained in writing.
Results
Eighty patients were randomly allocated to receive either oxpentifylline or a placebo. Table I shows the characteristics of the patients in each treatment group at baseline. There were no differences between treatment groups or between centres, or between our patients and those surveyed in a recent epidemiological study of patients with leg ulcers." The patients were quite healthy for their age and were of good nutritional state, as indicated by body mass index and plasma albumin concentration. One patient in the placebo group was withdrawn from the study when a dermatologist diagnosed pemphigoid in an atypical ulcer.
Complete healing of the reference ulcer occurred in
The results are shown in figure 1 . By the end of the study 64% of reference ulcers had healed in the patients treated with oxpentifylline, compared with 34% in those treated with a placebo (log rank test x2,= 4-78, p=0-03; odds ratio=1 81, 95% confidence interval 1 20 to 2 71). This result was significant. BMJ VOLUME 300
to baseline was seen in 35 of the 38 patients receiving oxypentifylline compared with 26 of the 42 patients receiving a placebo (X2= 10-0, p=0O002).
The tolerability of the treatment was studied. Unwanted effects were comparable between the two treatment groups, with 17 of the 38 patients (45%) who received oxpentifylline and 14 of the 42 patients (33%) who received a placebo complaining of side effects (X2l = I 1, p= 0 30). There was an excess of drop outs in the group treated with a placebo (9/42 (21%)) compared with the group treated with oxpentifylline (3/38 (8%)), but this difference was not significant ( ,=2 -9, p=009). Most of the drop outs occurred early in the study, but in only one of these patients was there evidence of a reduction in the area of the ulcer. This particular patient was receiving oxpentifylline. The three patients taking oxpentifylline who withdrew from the study did so because of oedema and depression, vomiting, and dyspepsia and diarrhoea. Seven of the patients taking placebo withdrew because of purpura, skin rash, dizziness, diarrhoea (two patients), cellulitis and pain, and headache and nausea; the two others dropped out because of poor compliance and because an ulcer was diagnosed as pemphigoid. discrepancy between the incidence of adverse events and the incidence of drop out for each treatment group suggests that other factors, such as failure of the ulcer to respond, rather than the treatment itself might have been responsible for patients dropping out of the study. Possible confounding factors were studied to see whether these had any effect on the healing of ulcers. The dressing and bandaging methods used were compared between the treatment groups but no differences were found. The effects of centre, the size of the ulcer at baseline, the length of history of venous disease, the duration of the current episode of disease, and the type of conservative treatment used were all studied for possible interactions with healing. No such interactions were detected.
Discussion
We have confirmed a report that oxpentifylline might be effective in healing venous ulcers of the leg when added to a regimen of compression bandaging. 6 The effect of different dressings on the healing of ulcers has been the subject of extensive research, but few of the studies have been properly controlled. A review of the subject found little evidence to show that particular dressings made any difference to healing rates.' High healing rates have recently been reported with a four layer compression bandaging method on its own,' but this study had an unusual design and used historical controls. The value of adequate two layer compression bandaging is well established.1 '3 Although pharmacological treatment has been advocated for the healing of venous ulcers, the few studies * Oxpentifylline (n=38) o Placebo (n=42) 
Introduction
The use of thiazides for treating arterial hypertension has been criticised. The arguments have been that thiazides do not reduce excess mortality, do not reduce the incidence of myocardial infarction, increase known risk factors, and produce more adverse effects than previously realised. As no treatment has yet shown a clear reduction in mortality or morbidity from acute myocardial infarction interest has focused on the risk factors and adverse effects. Evidence against thiazides was substantiated by a Medical Research Council trial, which compared treatment with a fixed dose of bendrofluazide (10 mg/day) or a titrated dose of propranolol with placebo. There was no basis for choosing a dose of 10 mg bendrofluazide.
We investigated the relevant dose range of bendrofluazide for treating mild to moderate arterial hypertension as this could affect both the choice and outcome of treatment.
Methods
Selection ofpatients-Patients aged 25-70 presenting to general practices in Zealand, Denmark, with newly diagnosed or previously treated arterial hypertension (up to two drugs) who gave informed consent were eligible for the study.
Patients were excluded if they were pregnant or lactating; had had a myocardial infarction or stroke within the past six months; had angina pectoris; were being treated for heart failure, gout, or uncontrolled diabetes mellitus or with drugs that reduced lipid concentrations; were intolerant of bendrofluazide; had reduced kidney function (creatinine concentration >150 [tmol/l); did not take 80-120% of the prescribed tablets while receiving a placebo at the start of the study.
Study design-Patients whose blood pressure was between 100 and 120 mm Hg after they had taken placebo for six weeks were randomly allocated in blocks of 10 on a double blind basis to receive placebo or bendrofluazide at a dose of 1 25, 2-5, 5, or 10 mg a day. Randomisation was performed from a list of computer generated numbers. The 10 mg dose was chosen because this was used in the Medical Research Council's trial and the 2 5 and 5 mg doses because they are recommended by the joint national committee on detection, evaluation, and treatment of high blood pressure.' The dose of 1 25 mg was believed to represent a point on the lower part of the dose-response curve. The active tablets contained 573 mg potassium chloride and either 1 25 mg or 2-5 mg bendrofluazide (Centyl K, Leo Pharmaceutical Products). Placebo and active tablets were identical in appearance and taste. All patients received four tablets daily, two in the morning and two at lunch. Those receiving fewer than four active tablets daily were given the active tablets in the morning. Patients were assessed on an outpatient basis for four, 10 , and 12 weeks after randomisation. Biochemical variables were measured before randomisation and at the end of the study; these variables included total cholesterol, apolipoprotein A I, apolipoprotein B, sodium, potassium, glucose, fructosamine, urate, and creatinine concentrations. The study was approved by the local ethical committee.
Methods ofassessment-The patient's blood pressures were measured twice, in the sitting position after five
